Phagelux AgriHealth utilizes phages, other biologics, and related or enabling technologies to create novel antibacterial products and solutions. These products address bacterial problems across multiple segments of agriculture, particularly targeting antibiotic resistant strains of bacteria. Phagelux AgriHealth has research labs and manufacturing facilities in North America and China. The Company aims to be a leading global Bio-agricultural company.
Phagelux AgriHealth has four franchises: crop sciences, animal health, food safety and feed additives. The Company currently sells five crop sciences products, three food safety products and five animal health products (not all products available in all markets yet). Additional products are in development or under regulatory review.
30+ years experience in building life sciences companies. Investor in life sciences and agricultural
MA from Harward University. 10+ years experience in leading strategic and BD process in global phage company.
MBA. Rich experience in phage product registration and project cooperation.
Extensive experience in financial management, including IPO process.
Ph.D in Microbiology. 10 years developing phage products, with focus on food safety and treatment of agricultural diseases.
Extensive experience in life sciences products sales and market management.
Ph.D in Molecular biology. 10+ years experience in managing phage product development and creating new phage platforms.
Ph.D in Agronomy. Strong expertise in horticultural science and plant nutrition. Industry leader in phage product development and related technologies.
Currently serves as Chairman, Director, or investor for multiple agriculture companies. Previously member of board of Managing Directors of BI and heading BI’s 4.5b+ Euro animal health division.
Currently serves as Board Member, Investor and Advisor to multiple companies with a focus on life sciences. Previously Executive VP - President of Elanco Animal Health Europe, Head of Bayer Animal Health.
Founded and invested by the Management and Wuxi AppTec.
First research lab established in Nanjing.
Acquisition of Omnilytics, to obtain R&D and production capacity in North America and to start to implement a global strategy
Round A financing completed.
Round B financing completed.
Spun off from Phagelux HumanHealth.
Bring in strategic investor Wuxi Guolian.